Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Clinical trial NCT04331626 · UNKNOWN
Trial details
- NCT number
- NCT04331626
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-01
- Primary completion
- 2022-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.